Scarica l'app Stockscreener
190.29
1.65%
3.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance
AbbVie Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com
Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest
4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha
IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
What drives AbbVie Inc. stock priceFree Technical Analysis Support - printweek.in
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
Is AbbVie Inc. a good long term investmentMassive stock growth - printweek.in
What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks
AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks
AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire
AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks
Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox
Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit
AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks
AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks
AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):